Please use this identifier to cite or link to this item:
http://hdl.handle.net/10668/11806
Title: | Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. |
Authors: | Martinez-Martinez, Laura Lleixà, Ma Cinta Boera-Carnicero, Gemma Cortese, Andrea Devaux, Jérôme Siles, Ana Rajabally, Yusuf Martinez-Piñeiro, Alicia Carvajal, Alejandra Pardo, Julio Delmont, Emilien Attarian, Shahram Diaz-Manera, Jordi Callegari, Ilaria Marchioni, Enrico Franciotta, Diego Benedetti, Luana Lauria, Guiseppe de la Calle Martin, Oscar Juárez, Cándido Illa, Isabel Querol, Luis |
Keywords: | Antibodies;CIDP;HLA DRB1*15;NF155 |
metadata.dc.subject.mesh: | Adult Aged Autoantibodies Autoantigens Case-Control Studies Cell Adhesion Molecules Female Gene Frequency Genetic Predisposition to Disease Genotype HLA-DRB1 Chains Humans Male Middle Aged Nerve Growth Factors Polyradiculoneuropathy, Chronic Inflammatory Demyelinating |
Issue Date: | 16-Nov-2017 |
Abstract: | The aim of the research is to study the human leukocyte antigen (HLA) class II allele frequencies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) associated with anti-neurofascin 155 (NF155) antibodies. Thirteen anti-NF155+ and 35 anti-NF155 negative (anti-NF155neg) CIDP patients were included in a case-control study. The frequencies of the DRB1 HLA allele were analyzed in all patients while DQ frequencies were only studied in patients sharing the DRB1*15 allele. In silico HLA-peptide binding and NF155 antigenicity, predictions were performed to analyze overlap between presented peptides and antigenic regions. DRB1*15 alleles (DRB1*15:01 and DRB1*15:02) were present in 10 out of 13 anti-NF155+ CIDP patients and in only 5 out of 35 anti-NF155neg CIDP patients (77 vs 14%; OR = 20, CI = 4.035 to 99.13). DRB1*15 alleles appeared also in significantly higher proportions in anti-NF155+ CIDP than in normal population (77 vs 17%; OR = 16.9, CI = 4.434 to 57.30). Seven anti-NF155+ CIDP patients (53%) and 5 anti-NF155neg CIDP patients had the DRB1*15:01 allele (OR = 7, p = 0.009), while 3 anti-NF155+ CIDP patients and none of the anti-NF155neg CIDP patients had the DRB1*15:02 allele (OR = 23.6, p = 0.016). In silico analysis of the NF155 peptides binding to DRB1*15 alleles showed significant overlap in the peptides presented by the 15:01 and 15:02 alleles, suggesting functional homology. DRB1*15 alleles are the first strong risk factor associated to a CIDP subset, providing additional evidence that anti-NF155+ CIDP patients constitute a differentiated disease within the CIDP syndrome. |
URI: | http://hdl.handle.net/10668/11806 |
metadata.dc.identifier.doi: | 10.1186/s12974-017-0996-1 |
Appears in Collections: | Producción 2020 |
Files in This Item:
File | Size | Format | |
---|---|---|---|
PMC5691853.pdf | 517,38 kB | Adobe PDF | View/Open |
This item is protected by original copyright |
This item is licensed under a Creative Commons License